By modulating innate immunity, the controller of the immune system, Lecinoxoids can potentially target a spectrum of immune-inflammatory diseases including cardiovascular diseases, NASH/Liver fibrosis, renal fibrosis and others.

The lead drug from the lecinoxoids platform, VB-201, is an oral small molecule that has been administered to more than 600 patients. In an exploratory Phase 2 trial, using a PET-CT  VB-201 has demonstrated significant reduction of atherosclerosis vascular inflammation, meeting the primary endpoint of the sub-study.  

Beyond VB-201, VBL has developed 2nd and 3rd generation structurally-related chemical compounds. The company has observed promising pre-clinical results in NASH and renal fibrosis models in some molecules, such as VB-201 and VB-703.

The recently granted U.S. Patent No. 10,022,388, entitled “Oxidized Lipids and Treatment or Prevention of Fibrosis”, provides VBL with intellectual property protection for the use of Phase-2 ready candidate VB-201, and additional lecinoxoid candidates, for treatment of fibrosis until November 2035, before potential extensions.